Isotretinoin for Proliferative Vitreoretinopathy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Isotretinoin for Proliferative Vitreoretinopathy (NCT01445028), a non-randomized phase 4 study. The primary outcome is Rate of Retinal Attachment.

2. Clinical Question

The study’s stated purpose is to evaluate oral isotretinoin in relation to recurrent retinal detachment associated with PVR. The registry describes PVR as secondary scarring on and around the retina and identifies it as an important cause of retinal re-detachment. Its summary says isotretinoin inhibits growth of cells responsible for PVR; that is the stated rationale, not a reported finding from this study.

The central interpretive question is limited by the design and record. This is a non-randomized, unmasked, parallel study, and no comparator without isotretinoin is described. The two groups have different clinical labels, so their outcomes would not automatically represent a like-for-like treatment comparison even if results were available. The registry record does not report an outcome analysis for retinal attachment. It therefore does not establish an observed attachment result or a treatment effect.

3. Trial Design

This completed study is listed as PHASE4 and has a parallel, non-randomized design with no masking. Wills Eye is named as the sponsor. The registry lists enrollment of 109 and identifies proliferative vitreoretinopathy as the condition. The study period is recorded as starting in 2011-09, with primary completion in 2013-08. These dates and status describe the registry entry; they do not supply details about participant follow-up or the conduct of individual assessments.

The intervention is oral isotretinoin. The registry names two groups: “Primary, High-risk Retinal Detachment” and “Recurrent RD Associated With PVR.” The arm descriptions associate isotretinoin with recurrent retinal detachment in both groups. The record does not describe a separate untreated, placebo, or active-comparator group. Because allocation is non-randomized, the groups should not be treated as randomized arms or as a like-for-like control comparison. The basis for assigning participants to these groups is not reported in the registry record.

The primary endpoint is retinal attachment at 3 months. The record says all patients will be evaluated at that time, but the detailed assessment procedure, criteria for attachment, and handling of assessments outside that time point are not reported in the registry record. One primary outcome measure is listed. The registry reports zero analyses, so no analyzed outcome results are available in the record.

The specific recruitment process, eligibility criteria, isotretinoin dose and duration, adherence procedures, and co-interventions are not reported in the registry record. Nor is a protocol-level statistical analysis plan reported. These omissions matter because the record gives the broad design and endpoint but not enough detail to reconstruct how participants entered each group or how the planned outcome was to be analyzed.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Rate of Retinal Attachment, measured over 3 months.

The primary endpoint is the rate of retinal attachment, measured in participants at 3 months. The outcome description says that all patients will be evaluated for retinal attachment at that time. The registry classifies the measure as a participant count, so the intended result concerns how many participants meet the endpoint, rather than a continuous measurement such as retinal thickness.

In general, an endpoint should translate the study question into an outcome that can be assessed consistently. Retinal attachment is relevant to this study’s stated focus on recurrent retinal detachment associated with PVR. A specified assessment time also gives readers a point at which to understand the outcome. Here, however, the registry does not report the detailed definition of attachment, the assessment method, or whether additional assessments informed the primary analysis. Those details are not reported in the registry record.

The word “rate” in the outcome title should not be mistaken for a posted result. The record includes no analysis of the primary endpoint, and no attachment counts or estimates are reported. It is therefore possible to describe what the study planned to measure, but not the observed frequency of retinal attachment or the precision of an estimated result.

In general, interpretation of a binary endpoint depends on how events and missing assessments are classified, as well as on the number of participants contributing data. The registry record does not report those analysis details for this endpoint. The calculated tables and plots on the page should be read alongside the record’s limitations and not as a substitute for an unreported primary analysis.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical methods help connect a study question to the data used to answer it. In this record, the planned primary outcome is a count of participants with retinal attachment assessed at 3 months. The record identifies the outcome but does not post an analysis. The discussion below explains general concepts relevant to this design; it does not describe unreported methods as if they were used in the trial.

What does a participant count represent?

For a binary outcome, each participant is classified according to whether the defined event or state occurred. A count can then summarize how many participants meet the endpoint in a group. In general, a count alone does not convey the full uncertainty of an estimate. Readers also need the number of participants assessed and a clear definition of the endpoint. Here the registry identifies the measure as a participant count and names retinal attachment at 3 months, but it does not post attachment counts, analysis denominators, or detailed endpoint criteria.

Why does the design affect interpretation?

Random allocation is one way to make comparison groups more similar, on average, with respect to measured and unmeasured characteristics. This study is listed as non-randomized, so that protection against systematic group differences cannot be assumed. In general, clinical differences that influence group assignment may also be related to outcomes. The registry does not describe the assignment process or report adjustment methods, so readers cannot determine from this record how such differences were addressed.

The parallel structure means the groups are listed alongside one another, but that alone does not make them a controlled treatment comparison. Both groups are described as receiving oral isotretinoin, and their labels distinguish primary, high-risk retinal detachment from recurrent retinal detachment associated with PVR. A comparison between those groups would answer a different question from a randomized comparison of isotretinoin with no isotretinoin or another treatment. No such comparator is described in the record.

What does lack of masking mean?

The registry lists masking as none. In general, masking can reduce the influence of expectations on subjective assessments or on decisions made during follow-up. Whether masking would materially affect this particular endpoint depends on its assessment procedures, which are not reported in the registry record. The absence of masking is a design feature readers should recognize, not proof that any assessment was biased.

How should uncertainty be read?

In general, a confidence interval gives a range of values compatible with the data and the method used to calculate it. Its width reflects statistical precision, with wider intervals indicating less precise estimates. A p-value, when reported, summarizes how compatible the observed data are with a specified null model under the assumptions of the analysis; it is not a measure of clinical importance. The registry record does not report a primary estimate, confidence interval, or p-value, so those concepts cannot be applied to a posted retinal-attachment result.

For binary outcomes, the chosen effect measure and its interval would also matter. An absolute difference describes the contrast in proportions, while relative measures describe a contrast on a ratio scale. These are general options, not methods reported for this study. The record does not identify an effect measure or a model for the primary endpoint.

What is over-dispersion, and is it relevant?

In general, over-dispersion occurs when observed variability is greater than a statistical model expects. It can affect uncertainty estimates in models that assume a particular variance structure. The posted primary endpoint is described as a participant count for a binary outcome, and no model or over-dispersion assessment is reported in the registry record. There is therefore no basis to say that an over-dispersion adjustment was used or was needed.

What do the sample-size illustrations mean?

The sample-size section is a planning illustration computed from an observed effect, not the trial’s own design. Its stated assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. For non-time-to-event outcomes, the illustrations express participants per arm for 80% power or another displayed power level; time-to-event tables instead give a total number of events. These are planning quantities, not observed power and not evidence that the study achieved a particular level of power.

The registry record does not report a trial-specific sample-size justification or the assumptions used to plan enrollment. Since the primary outcome analysis and observed effect are not posted, a planning illustration should not be read as a reconstruction of the trial’s design or as an estimate of its result. The illustration cannot repair the absence of an analyzed endpoint.

What can be concluded from the posted analysis fields?

The record lists one outcome measure and zero analyses. That distinction is important: a listed endpoint documents what was to be evaluated, while an analysis would provide results based on observed data and a stated method. The registry does not report the analysis population, covariate adjustment, missing-data procedure, or handling of protocol deviations. Those methods are not reported in the registry record and should not be inferred from the design labels or from the sample-size illustration.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Primary, High-risk Retinal Detachment", "Recurrent RD Associated With PVR")
n      <- c(58, 51)
events <- c(50, 42)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Primary, High-risk Retinal Detachment  58  50  86.2  74.6  93.9  75.1  92.8  75.0  92.8
ARM  Recurrent RD Associated With PVR  51  42  82.4  69.1  91.6  69.7  90.4  69.7  90.4

11. Multiplicity, Missing Data and Analysis Populations

Multiplicity concerns the risk of misleading results when several outcomes, comparisons, time points, or analyses are examined. In general, a prespecified primary outcome can help focus interpretation, while adjustment or other strategies may be used when multiple statistical tests are planned. The registry lists one primary outcome measure: retinal attachment at 3 months. It does not report an analysis, and the statistical plan for any additional outcomes or comparisons is not reported in the registry record. No multiplicity procedure is reported.

The absence of posted analyses means there are no reported primary or secondary test results to assess for multiplicity. The registry’s count of one outcome measure should not be treated as proof that no other outcomes were collected; it describes the outcome information listed in this record. The complete outcome collection plan is not reported in the registry record.

Missing data are also important for a participant-level endpoint. In general, a participant without an ascertainable endpoint cannot automatically be classified as having or not having retinal attachment. The analysis needs a stated approach to missing assessments, along with the number of participants assessed. The registry says all patients will be evaluated at 3 months, but it does not report the number with observed assessments or how missing assessments would be handled. That information is not reported in the registry record.

The analysis population is likewise unspecified. The record does not say whether the planned analysis included all enrolled participants, only those who received the intervention, or another defined group. It does not describe exclusions or protocol deviations. These omissions limit the ability to judge whether an eventual analysis would represent all enrolled participants or a selected subset.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

The registry’s serious-adverse-event entries list 0 affected among 58 at risk in the primary, high-risk retinal-detachment group, and 0 affected among 54 at risk in the recurrent retinal detachment associated with PVR group. The corresponding other-adverse-event fields also list 0 affected among 58 and 54 at risk. These are the figures recorded in the adverse-event fields for the two groups.

These counts should be read as descriptive entries, not as a comparison of treatment safety. Both groups are associated with isotretinoin, and the record does not describe a control group. The entries do not provide event definitions, collection procedures, follow-up duration for safety, or a detailed account of which events were monitored; these details are not reported in the registry record. A zero in a listed field does not establish that no unlisted or unrecorded event occurred.

Deaths are not reported in the adverse-event entries. That is different from a reported count of zero deaths. The safety fields also do not answer the primary question about retinal attachment. They should be considered separately from the outcome measure and from any causal interpretation of treatment effects.

13. What the Result Does, and Does Not, Mean

The record establishes that a completed, non-randomized study of oral isotretinoin listed retinal attachment at 3 months as its primary outcome. It identifies two retinal-detachment groups, describes the intervention in both, and reports adverse-event fields for those groups. These details are useful for understanding the question the study set out to address.

The record does not establish the primary outcome result. It lists zero analyses and provides no attachment counts, effect estimate, uncertainty interval, or p-value. Without an analyzed outcome and its denominator, readers cannot judge the frequency of retinal attachment or the precision of any group estimate. The listed adverse-event counts do not fill that gap because safety outcomes are distinct from retinal attachment.

The design also limits what a comparison could mean. Allocation was non-randomized, masking was absent, and the two groups have different clinical labels. Both are described as receiving isotretinoin, with no untreated or other-treatment comparator reported. Even if group-specific attachment results were available, a difference between these groups would not by itself isolate the effect of isotretinoin.

In general, a study’s biological rationale and its observed clinical results are separate things. The registry summary states that isotretinoin inhibits growth of cells responsible for PVR and describes the study’s purpose. That rationale does not constitute evidence of an observed retinal-attachment result in this record. The result and its precision are not reported in the registry record.

The sample-size illustrations are planning tools based on an observed effect, not trial findings and not observed power. They cannot be used to assert that the study succeeded or failed to detect an effect. The appropriate reading is therefore descriptive: the registry records the design and endpoint, but does not provide the primary analysis needed to answer the clinical question.

14. Why This Trial Matters Statistically

This trial matters statistically because it illustrates the difference between a registered endpoint and a reported result. Retinal attachment at 3 months is clearly named as the primary measure, but the record lists zero analyses. A planned question is not the same as an answer: without the observed endpoint data and analysis, readers cannot assess the estimate or its precision.

It also highlights why a study’s design labels must shape interpretation. A parallel study is not necessarily a controlled comparison, and two intervention groups do not automatically provide a treatment contrast. Here, allocation is non-randomized, both groups are described as receiving oral isotretinoin, and the group labels refer to different retinal-detachment contexts. Those features prevent treating one group as the control for the other.

The record also shows why safety counts and efficacy outcomes should remain distinct. The adverse-event fields contain zero affected for the listed categories and at-risk counts, while deaths are not reported. Those entries may be described as recorded, but they do not establish a retinal-attachment outcome or a comparative safety effect.

Finally, planning illustrations should not be mistaken for results. Sample-size calculations can help express what a future study might need under stated assumptions. They do not recover a missing analysis, establish observed power, or explain the trial’s own design when a protocol-specific justification is absent. The registry record does not report the statistical plan, missing-data procedures, or analysis population. Recognizing those boundaries is essential to a transparent reading of the posted information.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific details needed to assess the result are not reported in the registry record. The assignment process for the non-randomized groups is unspecified, as are eligibility criteria and the characteristics used to define high-risk retinal detachment or recurrent retinal detachment associated with PVR. Without those details, readers cannot assess how participants entered each group or how comparable the groups might have been.

The intervention description does not state isotretinoin dose, treatment duration, adherence, or concomitant care. The registry also does not provide a detailed retinal-attachment definition or assessment procedure. Although the intended assessment is at 3 months, information about additional assessments and follow-up beyond that point is not reported in the registry record.

Most importantly, no primary outcome analysis is posted. The record does not give attachment counts, analysis denominators, an effect estimate, or uncertainty. It also does not describe the analysis population, statistical model, adjustment strategy, or missing-data handling. The relation between listed enrollment and the group-specific adverse-event at-risk counts is not explained in the registry record, so those counts should not be used as denominators for the primary endpoint.

There is no described control group without isotretinoin. The non-randomized design and different group labels further limit causal interpretation. The adverse-event entries are limited to the fields displayed; event definitions, monitoring procedures, and deaths are not reported. These limitations mean the registry can describe the study’s broad design and planned endpoint, but not establish a treatment effect or provide a complete account of outcome ascertainment.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Isotretinoin for Proliferative Vitreoretinopathy — NCT01445028.
• Registry record last updated 2018-06-01; status last verified 2018-04.
• Results first posted 2017-05-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01445028 is listed as a completed PHASE4 study sponsored by Wills Eye. The registry describes a parallel, non-randomized design with no masking and enrollment of 109. The intervention is oral isotretinoin, described for both the primary, high-risk retinal-detachment group and the recurrent retinal detachment associated with PVR group.

The primary outcome is the rate of retinal attachment, assessed at 3 months. The record lists one outcome measure and zero analyses, so no primary outcome result is available in the registry record. Adverse-event fields list 0 serious events among 58 at risk in the primary, high-risk group and 0 among 54 at risk in the recurrent PVR group; deaths are not reported.

The design does not describe a like-for-like control comparison, and the registry does not report the protocol-level statistical plan, analysis population, or missing-data methods. The posted record supports a description of the study, but not a conclusion about the retinal-attachment result or a causal effect of isotretinoin.